ERBB2 and breast carcinoma: Triple-negative breast cancer (TNBC) is known to be refractory to major drugs used in the treatment of breast cancers because this sub-type of breast cancer does not express the usual drug-targeted receptors such as progesterone, oestrogen, or human epidermal growth factor receptor 2 (HER2).